WallStSmart

Allurion Technologies, Inc. (ALUR)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 382094% more annual revenue ($65.77B vs $17.21M). MRK leads profitability with a 13.6% profit margin vs -1.9%. MRK earns a higher WallStSmart Score of 50/100 (D+).

ALUR

Avoid

34

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.0

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ALUR.

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALUR1 strengths · Avg: 10.0/10
EPS GrowthGrowth
71.2%10/10

Earnings expanding 71.2% YoY

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

ALUR4 concerns · Avg: 2.5/10
Market CapQuality
$8.96M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Revenue GrowthGrowth
-0.5%2/10

Revenue declined 0.5%

Free Cash FlowQuality
$-6.54M2/10

Negative free cash flow — burning cash

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ALUR

The strongest argument for ALUR centers on EPS Growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : ALUR

The primary concerns for ALUR are Market Cap, Return on Equity, Revenue Growth.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

ALUR profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

MRK carries more volatility with a beta of 0.20 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 34/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Allurion Technologies, Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. The company is headquartered in Natick, Massachusetts.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?